X
AstraZeneca cancer drugs approved in Japan
https://pharmaphorum.com/r-d/astrazenecas-cancer-drugs-approved-japan/
Lynparza
Tesaro and Roche to combine drugs in bladder cancer trials
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
Lynparza first PARP drug to show promise in breast cancer
Data sets AZ up to file Lynparza in new indication
Cancer market commentary: 3 highlights from ESMO (Part 1)
Commentary on key cancer data from ESMO by Stephanie Hawthorne
